On the other hand, conjugation of the therapeutic peptides with BBB shuttle peptides is known to increase the applicability of these peptides [54,55] For example, inhibition of KV1.2 may have beneficial effects in epilepsy associated with gain of function mutations of KV1.2 [14]. Here, KCNA2 is linked to epilepsy.